As the CEO of Myos, I want to personally thank you for your trust in our company and your interest in the role muscle health plays in patient outcomes. I am sincerely grateful for your engagement with Myos MD with Fortetropin, and I want to wish you and your families a wonderful holiday season and a healthy, rewarding new year.
2025 has been a transformative year for Myos MD. Our relationships with physicians across a wide range of specialties have accelerated, not because of messaging or branding, but because clinicians are seeing what matters most—measurable improvements in muscle health, strength, and function. Your continued confidence in Fortetropin means more than I can express.
When I stepped into the CEO role nine years ago, I made a decision that Myos would never follow the path of most supplement companies. We were not going to market concepts. We were going to build a clinically credible platform grounded with validated outcomes, and measurable patient benefit. It was a path filled with uncertainty, and not without risk. If Fortetropin didn’t deliver real results, we had no right to expect support from clinicians like you.
That philosophy has shaped everything we do. Today, Myos has 14 studies, a growing portfolio of intellectual property, and an expanding set of investigations designed to address a central question in medicine: how do we preserve and restore muscle in populations where muscle loss is inevitable, accelerated, or consequential?
In 2025, we advanced that mission significantly. Rather than simply demonstrating that Fortetropin works, we focused on uncovering why it works. Our research effort included:
• UC Berkeley: Fortetropin helped animals maintain muscle under a 20% caloric restriction—a condition known to accelerate muscle loss. Instead of wasting, subjects demonstrated increased muscle protein synthesis. Highlighting potential relevance for GLP-1 treated patients.
• Adult and sarcopenic mouse models: Fortetropin led to measurable gains in muscle mass, independent of exercise—highlighting potential relevance aging patients.
• FSHD (Facioscapulohumeral Muscular Dystrophy) model: In an independently sponsored study, Fortetropin increased total muscle mass and improved treadmill performance, demonstrating anabolic and functional potential in a disease state marked by progressive muscle decline.
These studies are not marketing projects—they are scientific investments meant to answer the same questions you ask every day in your practice:
Does this intervention have a mechanism? Does it work? And does it matter clinically?
Why does this matter to your practice?
Because muscle is not cosmetic—it is metabolic, functional, and predictive. Whether in aging, chronic disease, orthopedic recovery, oncology, CKD, or patients on GLP-1 therapy, loss of muscle mass is loss of health.
Myos will continue to take the science road:
We will ask the difficult questions, fund the research, or get funded, and follow the data—wherever it leads. Our commitment is to ensure that when you recommend Fortetropin, you do so knowing the evidence is growing, the science is advancing, and the product is designed to make a meaningful difference in your patients’ lives.
Thank you for your trust, your curiosity, and your willingness to explore a new frontier of muscle biology with us. The work ahead is important—and we are honored to pursue it alongside you.
Warmest wishes,
Joe Mannello, CEO, Myos